A Phase 2/3 interventional study of Recombinant Human C1 Inhibitor and placebo in Hereditary Angioedema and Angioneurotic Edema, sponsored by Pharming Technologies B.V.. Completed at 1 site in Netherlands. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2013-02-22.
Sponsored by Pharming Technologies B.V. (part of Pharming Group N.V.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. Complement C1 Inhibitor Protein · Angioedemas, Hereditary.
Among the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary, this one is the 5th largest by enrollment, is one of 5 that started in 2005, is one of 2 in phase 2/3, and was the 2nd registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →None of the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →
Complement C1 Inhibitor Protein: first FDA approval 2014 (Ruconest), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 10 · Phase 4 2
First in 2004; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 32 across the 17 interventional studies. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 17 have an industry lead sponsor. The 9 most frequent:
This study is registered under Pharming Technologies B.V., one of the names counted as Pharming Group N.V.. Under that name alone:
Pharming Technologies B.V. is the lead sponsor of 22 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Pharming Group N.V. has 8 studies filed under Angioedemas, Hereditary — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Hereditary angioedema ("HAE") is a genetic disorder characterized by sudden recurrent attacks of local swelling (angioedema). These attacks are often painful and disabling, and, in some cases, life-threatening. "HAE" is caused by mutations in the "C1INH" gene that lead to a decrease in the blood level of functional "C1INH". This multi-center study was designed to assess the safety and tolerability, efficacy, and pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor ("rhC1INH") in the treatment of acute hereditary angioedema attacks.
Funding Source - FDA OOPD
A prospectively planned interim analysis will be performed on the double-blind data.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 IU/kg Recombinant human C1 inhibitor
Drug: Recombinant Human C1 Inhibitor
50 IU/kg Recombinant human C1 inhibitor
Drug: Recombinant Human C1 Inhibitor
Drug: placebo
Drug pages: Complement C1 Inhibitor Protein · Conestat alfa · C1 esterase inhibitor (human)
IV
Also known as: "rhC1INH", Ruconest, conestat alfa
saline solution
Also known as: saline, physiological salt solution
Time to Beginning of Relief of Symptoms
The time to beginning of relief of symptoms at the location that showed the first visual analogue scale ("VAS") score decrease of at least 20 mm from baseline score with persistence to the next timepoint, assessment timepoints were taken on pre-scheduled time-points after study drug administration: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours and 48 hours. Time to beginning of relief has been calculated as median time, by using the exact timepoints on which each assessment was performed.
Time frame: up to 48 hours after study drug administration
Time to Minimal Symptoms
The time to minimal symptoms was the time to minimal symptoms for an attack, assessed using the Visual Analogue Scale ("VAS") score. Symptoms were said to be minimal when the "VAS" score at all locations was below 20 mm. Assessment timepoints were: baseline, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours and 48 hours. Time to minimal symtoms has been calculated by using the exact timepoints on which each assessment was performed.
Time frame: up to 48 hours after study drug administration
During the double-blind phase of the study, patients were randomized once to receive 100 IU/kg "rhC1INH", 50 IU/kg "rhC1INH" or Saline in a ratio of 1:1:1. After treatment in the double-blind phase, patients with subsequent eligible attacks could be treated with open-label 50 IU/kg "rhC1INH".
| Milestone | 100 IU/kg "rhC1INH" | 50 IU/kg "rhC1INH" | Placebo | 50 IU/kg Open-label "rhC1INH" |
|---|---|---|---|---|
| Started | 13 | 12 | 13 | 0 |
| Completed | 13 | 12 | 13 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | 100 IU/kg "rhC1INH" | 50 IU/kg "rhC1INH" | Placebo | 50 IU/kg Open-label "rhC1INH" |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 62 |
| Completed | 0 | 0 | 0 | 52 |
| Not completed | 0 | 0 | 0 | 10 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 6 |
The time to beginning of relief of symptoms at the location that showed the first visual analogue scale ("VAS") score decrease of at least 20 mm from baseline score with persistence to the next timepoint, assessment timepoints were taken on pre-scheduled time-points after study drug administration: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours and 48 hours. Time to beginning of relief has been calculated as median time, by using the exact timepoints on which each assessment was performed.
| minutes | 100 IU/kg "rhC1INH" | 50 IU/kg "rhC1INH" | Placebo | 50 IU/kg Open-label "rhC1INH" |
|---|---|---|---|---|
| Time to Beginning of Relief of Symptoms | 68 (55 to 285) | 122 (29 to 250) | 258 (30 to 721) | 62.5 (15 to 1499) |
The time to minimal symptoms was the time to minimal symptoms for an attack, assessed using the Visual Analogue Scale ("VAS") score. Symptoms were said to be minimal when the "VAS" score at all locations was below 20 mm. Assessment timepoints were: baseline, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours and 48 hours. Time to minimal symtoms has been calculated by using the exact timepoints on which each assessment was performed.
| minutes | 100 IU/kg "rhC1INH" | 50 IU/kg "rhC1INH" | Placebo | 50 IU/kg Open-label "rhC1INH" |
|---|---|---|---|---|
| Time to Minimal Symptoms | 245 (125 to 270) | 246.5 (243 to 484) | 1101 (970 to 1494) | 145 (124 to 256) |
Collected over Treatment-Emergent-Adverse-Events (TEAEs) were defined as events with start from onset of study drug administration. Serious Adverse events and Adverse events for each arm with onset dates within 7 days of study drug administration have been listed.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 100 IU/kg rhC1INH | — | 0/13 (0%) | 2/13 (15.4%) |
| 50 IU/kg rhC1INH | — | 0/12 (0%) | 2/12 (16.7%) |
| Placebo | — | 0/13 (0%) | 3/13 (23.1%) |
| 50 IU/kg Open-label "rhC1INH" | — | 4/62 (6.5%) | 18/62 (29%) |
| Event | 100 IU/kg rhC1INH | 50 IU/kg rhC1INH | Placebo | 50 IU/kg Open-label "rhC1INH" |
|---|---|---|---|---|
| pneumonia - severeInfections and infestations | 0/13 | 0/12 | 0/13 | 1/62 |
| escherichia sepsisInfections and infestations | 0/13 | 0/12 | 0/13 | 1/62 |
| vertigo - severeNervous system disorders | 0/13 | 0/12 | 0/13 | 1/62 |
| hypersensitivityImmune system disorders | 0/13 | 0/12 | 0/13 | 1/62 |
| Event | 100 IU/kg rhC1INH | 50 IU/kg rhC1INH | Placebo | 50 IU/kg Open-label "rhC1INH" |
|---|---|---|---|---|
| headacheNervous system disorders | 2/13 | 0/12 | 0/13 | 12/62 |
| back painMusculoskeletal and connective tissue disorders | 0/13 | 1/12 | 0/13 | 0/62 |
| erythemaSkin and subcutaneous tissue disorders | 0/13 | 1/12 | 0/13 | 0/62 |
| injection site swellingGeneral disorders | 0/13 | 0/12 | 1/13 | 0/62 |
| myalgiaMusculoskeletal and connective tissue disorders | 0/13 | 0/12 | 1/13 | 0/62 |
| rash erythematousSkin and subcutaneous tissue disorders | 0/13 | 0/12 | 1/13 | 0/62 |
| throat irritationRespiratory, thoracic and mediastinal disorders | 0/13 | 0/12 | 1/13 | 0/62 |
| vertigoNervous system disorders | 1/13 | 0/12 | 0/13 | 2/62 |
| diarrheaGastrointestinal disorders | 0/13 | 0/12 | 0/13 | 3/62 |
| nauseaGastrointestinal disorders | 0/13 | 0/12 | 0/13 | 2/62 |
| Age, Categorical(Participants) | 100 IU/kg "rhC1INH" | 50 IU/kg "rhC1INH" | Placebo | 50 IU/kg Open-label "rhC1INH" | Total |
|---|---|---|---|---|---|
| <=18 years | 1 | 0 | 1 | 9 | 11 |
| Between 18 and 65 years | 11 | 12 | 12 | 30 | 65 |
| >=65 years | 1 | 0 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | 100 IU/kg "rhC1INH" | 50 IU/kg "rhC1INH" | Placebo | 50 IU/kg Open-label "rhC1INH" | Total |
|---|---|---|---|---|---|
| Female | 8 | 8 | 12 | 22 | 50 |
| Male | 5 | 4 | 1 | 17 | 27 |
The record gives a start of Jul 2005, a primary completion of Oct 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Complement C1 Inhibitor Protein · Conestat alfa · C1 esterase inhibitor (human)